An analysis of volumes, prices and pricing trends of the pediatric antiretroviral market in developing countries from 2004 to 2012

Janice Soo Fern Lee (), Luis Sagaon Teyssier (), Boniface Dongmo Nguimfack, Intira Jeannie Collins, Marc Lallemant, Joseph Perriens and Jean-Paul Moatti
Additional contact information
Janice Soo Fern Lee: Drugs for Neglected Diseases Initiative
Luis Sagaon Teyssier: SESSTIM - U912 INSERM - Aix Marseille Univ - IRD - Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale - IRD - Institut de Recherche pour le Développement - AMU - Aix Marseille Université - INSERM - Institut National de la Santé et de la Recherche Médicale
Boniface Dongmo Nguimfack: OMS / WHO - Organisation Mondiale de la Santé / World Health Organization Office [Genève, Suisse]
Intira Jeannie Collins: MRC CTU - Medical Research Council Clinical Trials Unit - UCL - University College of London [London]
Marc Lallemant: Drugs for Neglected Diseases Initiative
Joseph Perriens: OMS / WHO - Organisation Mondiale de la Santé / World Health Organization Office [Genève, Suisse]
Jean-Paul Moatti: SESSTIM - U912 INSERM - Aix Marseille Univ - IRD - Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale - IRD - Institut de Recherche pour le Développement - AMU - Aix Marseille Université - INSERM - Institut National de la Santé et de la Recherche Médicale

Post-Print from HAL

Abstract: The pediatric antiretroviral (ARV) market is poorly described in the literature, resulting in gaps in understanding treatment access. We analyzed the pediatric ARV market from 2004 to 2012 and assessed pricing trends and associated factors. Data on donor funded procurements of pediatric ARV formulations reported to the Global Price Reporting Mechanism database from 2004 to 2012 were analyzed. Outcomes of interest were the volume and mean price per patient-year ARV formulation based on WHO ARV dosing recommendations for a 10 kg child. Factors associated with the price of formulations were assessed using linear regression; potential predictors included: country income classification, geographical region, market segment (originator versus generic ARVs), and number of manufacturers per formulation. All analyses were adjusted for type of formulations (single, dual or triple fixed-dose combinations (FDCs)) Data from 111 countries from 2004 to 2012 were included, with procurement of 33 formulations at a total value of USD 204 million. Use of dual and triple FDC formulations increased substantially over time, but with limited changes in price. Upon multivariate analysis, prices of originator formulations were found to be on average 72 % higher than generics (p

Keywords: Price trends; Global Price Reporting Mechanism; Pediatric antiretroviral prices; Pediatric antiretroviral procurement; Pediatrics antiretroviral market (search for similar items in EconPapers)
Date: 2015-11-30
Note: View the original document on HAL open archive server: https://inserm.hal.science/inserm-01322527v1
References: View complete reference list from CitEc
Citations:

Published in BMC Pediatrics, 2015, 16 (1), pp.41. ⟨10.1186/s12887-016-0578-x⟩

Downloads: (external link)
https://inserm.hal.science/inserm-01322527v1/document (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:inserm-01322527

DOI: 10.1186/s12887-016-0578-x

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().